久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

美國PDS Biotechnology  
PDS Biotechnology Corporation 是一家非上市生物技術公司，致力于通過利用帶陽電荷的特殊合成脂質中新發現的屬性來推廣新一代免疫療法和疫苗。專有的 Versamune? 平臺納米技術，一旦與具體癌癥相關的分子相結合，經證實與臨床前癌癥模式中的領先臨床輔助治療相比，可實現更高的腫瘤衰退率（Cancer Immunology Immunotherapy, 2008, 57: (4) 517-530）。Versamune? 納米技術在開發新一代免疫療法方面實現了巨大了進步。PDS Biotechnology Corporation 正在開發治療子宮癌、頭頸癌和黑瘤等多發癌癥的主打產品。該技術還被用于開發預防流行病的疫苗。

PDS Biotechnology Corporation is a privately held biotechnology company founded to exploit the newly discovered properties of specific synthetic positively charged (cationic) lipids to commercialize a new generation of immunotherapies and vaccines. The proprietary Versamune? platform nanotechnology, when combined with specific cancer-associated molecules, has been demonstrated to lead to increased tumor regression rates compared to leading clinical adjuvants in pre-clinical cancer models (Cancer Immunology Immunotherapy, 2008, 57: (4) 517-530). The Versamune? nanotechnology presents a giant step forward in the development of the next generation of immunotherapies. PDS Biotechnology Corporation's lead products are being developed to treat prevalent cancers such as cervical cancer, head and neck cancer and melanoma. The technology is also being applied to the development of vaccines which are designed to protect against pandemic diseases.